Skip to main content
Erschienen in: Journal of General Internal Medicine 9/2020

Open Access 24.06.2020 | Concise Research Report

Should Asymptomatic and Low-Risk Individuals be Tested for SARS-CoV-2?

verfasst von: Ashwini R. Sehgal, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 9/2020

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

INTRODUCTION

Because people with asymptomatic SARS-CoV-2 infections are an important source of transmission, widespread testing has the potential to identify and isolate such individuals, quarantine their contacts, and prevent further spread. However, testing for a condition in a group with low disease prevalence may lead to numerous false positive results. This study quantifies the tradeoff between reducing transmission by true positives and unnecessary isolation and quarantine due to false positives.

METHODS

The impact of testing was modeled based on the following parameters: 1% prevalence of active infection, test sensitivity 90% and specificity 95%, reproduction number 0.9, and 5 contacts per case.15 Because performance of SARS-CoV-2 tests is not well established, the values that correspond to PCR-based tests for other respiratory viral infections were used.2, 3 The reproduction number R is the median value in the USA.4 Because individuals with positive test results will be instructed to isolate, R following a positive test was assumed to decrease to 0.1.5 The number of people subsequently infected by each infected case disease was calculated using the formula R + R2 + R3 + … = 1/(1−R)−1 when R < 1. For R = 0.9, this sum of 9.0 represents the number of new infections in a transmission chain and was applied to individuals with false negative results and to infected individuals who were not tested. The corresponding sum for a true positive case is 1.0, which assumes a reproduction number of 0.1 for the first transmission and 0.9 for subsequent transmissions.

RESULTS

In the base case, testing will result in 5.5 times more false positive than true positive results (Table 1). Testing will result in 72,000 fewer infections. Of the 351,000 people who will be isolated or quarantined, a substantial majority (297,000) will be isolated or quarantined because of false positive tests. With a higher prevalence of active infection, there will be 180,000 fewer infections, but a large number of people will still need to be isolated or quarantined. A highly specific test yields fewer false positives. About half (54,000) of the 113,400 people who must be isolated or quarantined will be because of true positive tests. A test that is both highly specific and sensitive will also greatly reduce the number of false negatives. At very high levels of test specificity, the number of people needed to isolate or quarantine (NNIQ) per infection prevented decreases and is minimally affected by variations in test sensitivity (Fig. 1).
Table 1
Simulated Results of One-Time Testing of 1 Million Asymptomatic and Low-Risk Individuals for SARS-CoV-2
 
Base case
Higher prevalence of active infection
Better test specificity
Better test sensitivity and specificity
Model parameters
• Prevalence of active infection: 1%
• Test sensitivity, specificity: 90%, 95%
• Reproduction number: 0.9 (0.1 after positive test)
• Contacts per case: 5
• Prevalence of active infection: 2.5%
• Test sensitivity, specificity: 90%, 95%
• Reproduction number: 0.9 (0.1 after positive test)
• Contacts per case: 5
• Prevalence of active infection: 1%
• Test sensitivity, specificity: 90%, 99%
• Reproduction number: 0.9 (0.1 after positive test)
• Contacts per case: 5
• Prevalence of active infection: 1%
• Test sensitivity, specificity: 99%, 99%
• Reproduction number: 0.9 (0.1 after positive test)
• Contacts per case: 5
Results of testing
• True positive: 9000 (0.9%)
• False positive: 49,500 (5.0%)
• True negative: 940,500 (94.1%)
• False negative: 1000 (0.1%)
• True positive: 22,500 (2.3%)
• False positive: 48,750 (4.9%)
• True negative: 926,250 (92.6%)
• False negative: 2500 (0.3%)
• True positive: 9000 (0.9%)
• False positive: 9900 (1.0%)
• True negative: 980,100 (98.0%)
• False negative: 1000 (0.1%)
• True positive: 9900 (1.0%)
• False positive: 9900 (1.0%)
• True negative: 980,100 (98.0%)
• False negative: 100 (0.01%)
Transmission chain of infection if testing
• From 9000 true positives: 9000 new cases
• From 1000 false negatives: 9000 new cases
• From 22,500 true positives: 22,500 new cases
• From 2500 false negatives: 22,500 new cases
• From 9000 true positives: 9000 new cases
• From 1000 false negatives: 9000 new cases
• From 9900 true positives: 9900 new cases
• From 100 false negatives: 900 new cases
Transmission chain of infection if no testing
• From 10,000 infected individuals: 90,000 new cases
• From 25,000 infected individuals: 225,000 new cases
• From 10,000 infected individuals: 90,000 new cases
• From 10,000 infected individuals: 90,000 new cases
Isolation and quarantine due to testing
• Isolation: 58,500 positive test results
• Quarantine: 292,500 contacts
• Isolation: 71,250 positive test results
• Quarantine: 356,250 contacts
• Isolation: 18,900 positive test results
• Quarantine: 94,500 contacts
• Isolation: 19,800 positive test results
• Quarantine: 99,000 contacts
Overall effect of testing
• 72,000 fewer infections
• 351,000 people isolated or quarantined
• 4.9 number of people needed to isolate or quarantine (NNIQ) per infection prevented
• 180,000 fewer infections
• 427,500 people isolated or quarantined
• 2.4 NNIQ
• 72,000 fewer infections
• 113,400 people isolated or quarantined
• 1.6 NNIQ
• 79,200 fewer infections
• 118,800 people isolated or quarantined
• 1.5 NNIQ

DISCUSSION

This analysis indicates that policy makers should avoid instituting mass testing of asymptomatic and low-risk individuals until a test with very high specificity becomes available. Determining test specificity will be challenging in the absence of a gold standard that definitively establishes the presence of absence of SARS-CoV-2. There are several possible approaches to clarify the magnitude of false positive results. A second test can be performed, preferably from a different manufacturer, to determine if it is negative. A serological test can be performed at a later date to determine if antibodies to SARS-CoV-2 develop as expected after infection. Individuals can also be followed over time to determine if they subsequently develop COVID-19 symptoms.
Several limitations must be considered in interpreting these results. The results do not apply to testing of symptomatic or high-risk groups. The actual values of model parameters have not been well established. The analyses assume that these parameters do not change over time. The number of contacts per infected individual (and therefore the number quarantined) may be higher or lower than the estimate used in these analyses. For example, the number of people who need to quarantine would be lower if the same individual is the contact of more than one infected person. Alternatively, much higher numbers of contacts, i.e., 10–30 per case, have been reported in some settings.6 As a result, it will be important to continue some social isolation restrictions to limit the number of people who must be quarantined. In addition, it is unclear whether contacts who have already recovered from COVID-19 or are known to have antibodies need to be quarantined. In contrast to more complex and less transparent models, these parameters and accompanying calculations can be easily modified for other scenarios and updated as the pandemic evolves.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

Literatur
1.
Zurück zum Zitat TRACE-COVID-19 project. Available at https://trace.oregonstate.edu Accessed May 28, 2020. TRACE-COVID-19 project. Available at https://​trace.​oregonstate.​edu Accessed May 28, 2020.
2.
Zurück zum Zitat Kokkinakis I, Selby K, Favrat B, Genton B, Cornuz J. COVID-19 diagnosis: clinical recommendations and performance of nasopharyngeal swab PCR. Rev Med Suisse. 2020;16:699-701.PubMed Kokkinakis I, Selby K, Favrat B, Genton B, Cornuz J. COVID-19 diagnosis: clinical recommendations and performance of nasopharyngeal swab PCR. Rev Med Suisse. 2020;16:699-701.PubMed
3.
Zurück zum Zitat Basile K, Kok J, Dwyer DE. Point-of-care diagnostics for respiratory viral infections. Expert Rev Mol Diagn. 2018;18:75-83.CrossRef Basile K, Kok J, Dwyer DE. Point-of-care diagnostics for respiratory viral infections. Expert Rev Mol Diagn. 2018;18:75-83.CrossRef
4.
Zurück zum Zitat Rt COVID-19. Available at https://rt.live Accessed May 28, 2020. Rt COVID-19. Available at https://​rt.​live Accessed May 28, 2020.
Metadaten
Titel
Should Asymptomatic and Low-Risk Individuals be Tested for SARS-CoV-2?
verfasst von
Ashwini R. Sehgal, MD
Publikationsdatum
24.06.2020
Verlag
Springer International Publishing
Erschienen in
Journal of General Internal Medicine / Ausgabe 9/2020
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-06000-z

Weitere Artikel der Ausgabe 9/2020

Journal of General Internal Medicine 9/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.